Article Data

  • Views 1041
  • Dowloads 162

Editorial

Open Access

USE OF TESTOSTERONE REPLACEMENT THERAPY AFTER RADICAL PROSTATECTOMY MIGHT KILL TWO BIRDS WITH ONE STONE FROM THE PERSPECTIVE OF MEN’S HEALTH AND DISEASE CONTROL

  • Jong Kil Nam1
  • Ki Soo Lee2
  • Tae Nam Kim3

1Department of Urology, Pusan National University Yangsan Hospital, Yangsan, Korea

2Departments of Urology, College of Medicine, Dong-A University College of Medicine, Busan, South Korea

3Department of Urology, Biomedical Research Institute of Pusan National University Hospital, Pusan National University School of Medicine, Busan, Korea

DOI: 10.15586/jomh.v16iSP1.271 Vol.16,Issue SP1,April 2020 pp.52-56

Published: 01 April 2020

*Corresponding Author(s): Tae Nam Kim E-mail: bigman1995@hanmail.net

PDF (300.98 kB)

Abstract

Testosterone plays an important role in promoting the differentiation and stimulation of prostate epi-thelial cells. Adding to the basic physiology of testosterone, several studies led to the dissemination of the historical androgen hypothesis that higher circulating androgen levels promote prostate cancer cell growth and make the tumor more aggressive. Whereas, the prostate saturation model accounted for the androgen sensitivity of testosterone stimulation in the prostate up to a saturation point, which occurred near the level of castration. Testosterone is related to prostate cancer metabolism in a com-plex manner; however, within the reference range, high or normal testosterone levels are expected to maintain benign and malignant prostate cells in a differentiated state. Accumulating evidence has suggested that testosterone replacement therapy (TRT) might prevent the development of prostate cancer and even reduce prostate cancer risk. There is no change in the clinical guidelines to be followed when considering TRT in patients with a history of prostate cancer, but it is necessary for the physician to inform patients of the positive effects of TRT on male health and prostate cancer.

Keywords

Testosterone, Prostatic Cancer, Men’s Health

Cite and Share

Jong Kil Nam,Ki Soo Lee,Tae Nam Kim. USE OF TESTOSTERONE REPLACEMENT THERAPY AFTER RADICAL PROSTATECTOMY MIGHT KILL TWO BIRDS WITH ONE STONE FROM THE PERSPECTIVE OF MEN’S HEALTH AND DISEASE CONTROL. Journal of Men's Health. 2020. 16(SP1);52-56.

References

1. Fujita K, Nonomura N. Role of androgen recep-tor in prostate cancer: A review. World J Mens Health 2019;37(3):288–95. https://doi.org/10.5534/wjmh.180040

2. Huggins C, Hodges CV. Studies on prostatic can-cer. The effect of castration, of estrogen and androgen injection on serum phosphatases in metastatic carcinoma of the prostate. CA Cancer J Clin 1972;22(4):232–40. https://doi.org/10.3322/canjclin.22.4.232

3. Gann PH, Hennekens CH, Ma J, et al. Prospective study of sex hormone levels and risk of prostate cancer. J Natl Cancer Inst 1996;88(16):1118–26. https://doi.org/10.1093/jnci/88.16.1118

4. Morgentaler A, Traish AM. Shifting the paradigm of testosterone and prostate cancer: The saturation model and the limits of androgen-dependent growth. Eur Urol 2009;55(2):310–20. https://doi. org/10.1016/j.eururo.2008.09.024

5. Wang K, Chen X, Bird VY, et al. Association between age-related reductions in testosterone and risk of prostate cancer—An analysis of patients’ data with prostatic diseases. Int J Cancer 2017;141(9):1783–93. https://doi.org/10.1002/ijc. 30882

6. Mearini L, Zucchi A, Nunzi E, et al. Low serum testosterone levels are predictive of prostate can-cer. World J Urol 2013;31(2):247–52. https://doi. org/10.1007/s00345-011-0793-x

7. Shin BS, Hwang EC, Im CM, et al. Is a decreased serum testosterone level a risk factor for prostate cancer? A cohort study of Korean men. Korean J Urol 2010;51(12):819–23. https://doi.org/10.4111/kju.2010.51.12.819

8. Tafuri A, Sebben M, Shakir A, et al. Endogenous testosterone mirrors prostate cancer aggressiveness: Correlation between basal testosterone serum levels and prostate cancer European Urology Association clinical risk classes in a large cohort of Caucasian patients. Int Urol Nephrol 2020;52(7):1261-9. https://doi.org/10.1007/s11255-020-02398-x

9. Schatzl G, Madersbacher S, Haitel A, et al. Associations of serum testosterone with microves-sel density, androgen receptor density and andro-gen receptor gene polymorphism in prostate cancer. J Urol 2003;169(4):1312–5. https://doi.org/ 10.1097/01.ju.0000056900.26628.16

 10. Lane BR, Stephenson AJ, Magi-Galluzzi C, et al. Low testosterone and risk of biochemical recur-rence and poorly differentiated prostate cancer at radical prostatectomy. Urology 2008;72(6):1240–5. https://doi.org/10.1016/j.urology.2008.06.001

 11. Massengill JC, Sun L, Moul JW, et al. Pretreatment total testosterone level predicts pathological stage in patients with localized prostate cancer treated with radical prostatectomy. J Urol 2003;169(5): 1670–5. https://doi.org/10.1097/01.ju.0000062674. 43964.d0

 12. Ferro M, Lucarelli G, Bruzzese D, et al. Low serum total testosterone level as a predictor of upstaging and upgrading in low-risk prostate cancer patients meeting the inclusion criteria for active surveillance. Oncotarget 2017;8(11): 18424–34. https://doi.org/10.18632/oncotarget. 12906

 13. Calof OM, Singh AB, Lee ML, et al. Adverse events associated with testosterone replacement in middle-aged and older men: A meta-analysis of randomized, placebo-controlled trials. J Gerontol A 2005;60(11):1451–7. https://doi.org/10.1093/gerona/ 60.11.1451

 14. Eaton NE, Reeves GK, Appleby PN, et al. Endogenous sex hormones and prostate cancer: A quantitative review of prospective studies. Br J Cancer 1999;80(7):930–4. https://doi.org/10.1038/sj.bjc.6690445

 15. Wallis CJ, Lo K, Lee Y, et al. Survival and cardio-vascular events in men treated with testosterone replacement therapy: An intention-to-treat obser-vational cohort study. Lancet Diabetes Endocrinol 2016;4(6):498–506. https://doi.org/10.1016/S2213-8587(16)00112-1

 16. Loeb S, Folkvaljon Y, Damber JE, et al. Testosterone replacement therapy and risk of favorable and aggressive prostate cancer. J Clin Oncol 2017;35:1430–6. https://doi.org/10.1200/JCO.2016.69.5304

 17. Kaplan AL, Hu JC. Use of testosterone replace-ment therapy in the United States and its effect on subsequent prostate cancer outcomes. Urology 2013;82(82):321–6. https://doi.org/10.1016/j.urology. 2013.03.049

 18. Kardoust Parizi M, Abufaraj M, Fajkovic H, et al. Oncological safety of testosterone replacement therapy in prostate cancer survivors after definitive local therapy: A systematic literature review and meta-analysis. Urol Oncol 2019;37(10):637–46. https://doi.org/10.1016/j.urolonc.2019.06.007

 19. Klap J, Schmid M, Loughlin KR. The relationship between total testosterone levels and prostate cancer: A review of the continuing controversy. J Urol 2015;193(2):403–13. https://doi.org/10.1016/j. juro. 2014.07.123

 20. Pastuszak AW, Pearlman AM, Lai WS, et al. Testosterone replacement therapy in patients with prostate cancer after radical prostatectomy. J Urol 2013;190(2):639–44. https://doi.org/10.1016/j. juro.2013.02.002

 21. Ahlering TE, Huynh LM, Towe M, et al. Testosterone replacement therapy reduces bio-chemical recurrence post-radical prostatectomy. BJU Int 2020;2. https://doi.org/10.1111/bju. 15042

 22. Hackett G. Type 2 diabetes and testosterone ther-apy. World J Mens Health 2019;37(1):31–44. https://doi.org/10.5534/wjmh.180027

 23. Nam YS, Lee G, Yun JM, et al. Testosterone replacement, muscle strength, and physical func-tion. World J Mens Health 2018;36(2):110–22. https://doi.org/10.5534/wjmh.182001

 24. Bell MA, Campbell JD, Joice G, et al. Shifting the paradigm of testosterone replacement ther-apy in prostate cancer. World J Mens Health 2018;36(2):103–9. https://doi.org/10.5534/wjmh. 170007

Abstracted / indexed in

Science Citation Index Expanded Created as SCI in 1964, Science Citation Index Expanded now indexes over 9,200 of the world’s most impactful journals across 178 scientific disciplines. More than 53 million records and 1.18 billion cited references date back from 1900 to present.

Social Sciences Citation Index Social Sciences Citation Index contains over 3,400 journals across 58 social sciences disciplines, as well as selected items from 3,500 of the world’s leading scientific and technical journals. More than 9.37 million records and 122 million cited references date back from 1900 to present.

Current Contents - Social & Behavioral Sciences Current Contents - Social & Behavioral Sciences provides easy access to complete tables of contents, abstracts, bibliographic information and all other significant items in recently published issues from over 1,000 leading journals in the social and behavioral sciences.

Current Contents - Clinical Medicine Current Contents - Clinical Medicine provides easy access to complete tables of contents, abstracts, bibliographic information and all other significant items in recently published issues from over 1,000 leading journals in clinical medicine.

SCOPUS Scopus is Elsevier's abstract and citation database launched in 2004. Scopus covers nearly 36,377 titles (22,794 active titles and 13,583 Inactive titles) from approximately 11,678 publishers, of which 34,346 are peer-reviewed journals in top-level subject fields: life sciences, social sciences, physical sciences and health sciences.

DOAJ DOAJ is a community-curated online directory that indexes and provides access to high quality, open access, peer-reviewed journals.

CrossRef Crossref makes research outputs easy to find, cite, link, assess, and reuse. Crossref committed to open scholarly infrastructure and collaboration, this is now announcing a very deliberate path.

Portico Portico is a community-supported preservation archive that safeguards access to e-journals, e-books, and digital collections. Our unique, trusted process ensures that the content we preserve will remain accessible and usable for researchers, scholars, and students in the future.

Submission Turnaround Time

Conferences

    Top